

REMARKS

Non-compliance

Applicants submit that the contentions made in the notice of non-compliance are erroneous. The status of the claims and the claim identifiers presented in the listing of claims submitted with the previous reply reflect the amendments that were entered via Applicants' preliminary amendment filed January 3, 2005. See, enclosed. See also, published claims in US patent publication No. 2006-0172407 A1. Favorable action is earnestly solicited.

The Commissioner is hereby authorized to charge any fees associated with this response to Deposit Account No. 13-3402.

Respectfully submitted,

/Anthony J. Zelano/

Anthony J. Zelano, Reg. No. 27,969
Attorney for Applicant(s)

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: SIMANDI-0002

Date: July 7, 2008

DO/EO WORKSHEET

U.S. Appl. No. 10/520145International Appl. No. 8903/07068Application filed by: 20 months 30 months

WIPO PUBLICATION INFORMATION:

Publication No.: WO /

Publication Language: English Japanese
 German French Other: _____

Screening Done by:

Publication Date: 15 Jan 05Not Published: U.S. only designated EP request

INTERNATIONAL APPLICATION PAPERS IN THE APPLICATION FILE:

- International Application (RECORD COPY)
 Article 19 Amendments
 PCT/IB/331
 PCT/IPEA/409 IPER (PCT/IPEA/416 on front)
 Annexes to 409
 Priority Document (s) No. 15

- International Appl. on Double Sided Paper (COPIES MADE)
 Request form PCT/RO/101
 PCT/ISA/210 - Search Report
 Search Report References
 Other: _____

RECEIPTS FROM THE APPLICANT (other than checked above):

- Basic National Fee (or authorization to charge)
 Description
 Claims
 Words in the Drawing Figure(s) - (# of dwgs. 15)
 Article 19 Amendments
 english transl. of annexes NOT present
 entered not entered:
 not a page for page substitution
 other:
 Annexes to 409
 english transl. of annexes NOT present
 entered not entered:
 not a page for page substitution
 other:

- Preliminary Amendment(s) Filed on: 1. 30 Jan 05 2. _____ 3. _____
 Information Disclosure Statement(s) Filed on: 2 Jan 05 2. _____ 3. _____
 Assignment Document
 Power of Attorney/ Change of Address
 Substitute Specification Filed on: 1. _____ 2. _____
 Small Entity
 Oath/ Declaration (executed)
 surcharge was paid at the time of filing
 DNA Diskette Sequence Listing
 Other: 1. _____ 2. _____

NOTES: LA. used as Specification Other:

35 U.S.C. 371 - Receipt of Request (PTO-1390)

3 Jan 05

Date Acceptable Oath/ Declaration Received

Date of Completion of requirements under 35 U.S.C. 371

102(e) Date

Date of Completion of DO/EO 903 - Notification of Acceptance

Date of Completion of DO/EO 905 - Notification of Missing Requirements

Date of Completion of DO/EO 906 - Notification of Missing 102(e) Requirements

Date of Completion of DO/EO 907 - Notification of Acceptance for 102(e) Date

Date of Completion of DO/EO 909 - Notification of Abandonment

Date of Completion of DO/EO 911 - Application Accepted Under 35 U.S.C. III

Date of Completion of DO/EO 916 - Notification of Defective Response

Date of Completion of DO/EO 920 - Notification to Comply w/ Seq. Requirements

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No. : PCT/EP2003/007068

International Filing Date : July 2, 2003

Priority Date(s) Claimed : July 2, 2002

Applicant(s) (DO/EO/US) : Frank MAYER et al.

Title: BACTERIAL CELL DIGESTION

PRELIMINARY AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SIR:

Prior to calculating the national fee, and prior to examination in the National Phase of the above-identified International application, please amend as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 5 of this paper.

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) Use of substances that bind to the components of the cytoskeleton, especially to EF-Tu, for cell digestion.

2. (Original) Use according to claim 1 for cell digestion of bacteria cells.

3. (Currently Amended) Use according to claim 1 or 2, characterized in that the substances bind to the EF-Tu in the area of the domain 2 (amino acids 205 to 298) and/or of the domain 3 (amino acids 299 to 349).

4. (Currently Amended) Use according to claim 1 one of the preceding claims, wherein the substances bind to the EF-Tu in the area of the amino acids 218 to 224 of the domain 2 and/or in the area of amino acids 317 to 328 and/or 343 to 354 of the domain 3.

5. (Currently Amended) Use according to claim 1 one of the preceding claims, wherein the substances contain partial segments of the amino acid sequences from the domains 2 and/or 3 with a length of at least four amino acids.

6. (Original) Use according to claim 5, wherein the partial segments have a length from 5 to 15 amino acids, especially from 6 to 12 amino acids.

7. (Currently Amended) Use according to claim 1 one of claims 1 to 5, wherein the substances contain the domain 3 of EF-Tu and no other domain of EF-Tu.

8. (Currently Amended) Use according to claim 1 one of the preceding claims, wherein the substances are chosen from linear or cyclic peptide compounds or peptide mimetic agents.

9. (Original) Process for digestion of cells, wherein components of the cytoskeleton are destabilized in the cells.

10. (Original) Process according to claim 9, wherein substances that bind to the components of the cytoskeleton are used for destabilization.

11. (Currently Amended) Process according to claim 9 or 10, wherein substances that bind to EF-Tu are used.

12. (Currently Amended) Process according to claim 9 one of claims 9 to 11, wherein substances are used that bind to the EF-Tu in the area of the domain 2 (amino acids 205 to 298) and/or domain 3 (amino acids 299 to 394), especially in the area of amino acids 218 to 224 of the domain 2 and/or in the area of amino acids 317 to 328 and/or 343 to 354 of the domain 3.

13. (Currently Amended) Process according to claim 12 one of claims 12 or 13, wherein substances are used that contain partial segments of the amino acid sequences from the domains 2 and/or 3 with a length of at least 4 amino acids, especially of at least 5 amino acids.

14. (Currently Amended) Process according to claim 10 one of claims 10 to 13, wherein nucleic acids are introduced into the cells that code for the substances that destabilize the cytoskeleton.

15. (Original) Process for producing a compound, wherein cells are used into which a sequence has been introduced, coding for a compound that destabilizes components of the cytoskeleton of the cells, the cells are cultivated and in this way the desired intracellular compound is obtained.

16. (Original) Process according to claim 15, wherein the desired compound is intracellularly produced by cultivation of cells and, in a second step, lysis of the cells is caused by induction of expression of the compound that destabilizes the cytoskeleton.

17. (Currently Amended) Process according to claim 16 one of claims 16 [sic],
wherein the desired compound is formed by heterologous expression.

18. (Currently Amended) Process according to claim 16 one of claims 16 [sic],
wherein the desired compound is formed by homologous expression.

19. (Currently Amended) Process according to claim 16 one of claims 16 to 20,
wherein induction takes place by quorum sensing.

20. (Currently Amended) Process according to claim 16 one of claims 16 to 20,
wherein the sequence that codes for a compound that destabilizes the cytoskeleton of the cells
in a construct is introduced into the cells, the construct containing additional regions that
allow an induction of the synthesis of the compound.

21. (Original) Construct, comprising a sequence that codes for a compound that
destabilizes components of the cytoskeleton of cells.

22. (Original) Construct according to claim 21, furthermore comprising a gene segment
that allows the induction of synthesis of the compound that destabilizes the cytoskeleton.

REMARKS

The purpose of this Preliminary Amendment is to eliminate multiple dependent claims in order to avoid the additional fee. Applicants reserve the right to reintroduce claims to canceled combined subject matter.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,



(Chg. No. 32572)

Anthony J. Zelano, Reg. No. 27,969
Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Boulevard, Suite 1400
Arlington, VA 22201
Direct Dial: 703-812-5311
Facsimile: 703-243-6410
Attorney Docket No.:DREISS-2

Date: January 3, 2005

AJZ:aap

K:\Dreiss\2\preliminary amendment.doc